SVB Securities raised the firm’s price target on Centessa to $11 from $6 and keeps an Outperform rating on the shares ahead of potential positive pipeline catalysts for the company’s orexin program in October 2023 and initial LockBody candidate LB101 Phase 1/2a updates in late 2023 or 2024. The firm cites Q2 results and the company’s nomination of 2nd LockBody candidate LB206 for solid tumor applications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CNTA:
- Centessa reports Q2 EPS (26c), consensus (49c)
- Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
- Is CNTA a Buy, Before Earnings?
- Centessa price target raised to $15 from $11 at BMO Capital
- Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors